Abstract
We have previously demonstrated expression of cytochrome P 450 3A (CYP3A) protein in pulmonary carcinomas and surrounding normal tissue, using immunohistochemistry. These results suggested that different CYP3A enzymes may be expressed in normal and tumour tissue. Therefore, the aim of the present study was to identify specific CYP3A enzymes expressed in normal human lung and lung tumours. Both normal lung tissue and tumour tissue from eight patients was analyzed for CYP3A4, CYP3A5 and CYP3A7 mRNA using a specific RT-PCR (reverse transcriptase-polymerase chain reaction) method. Identical samples were subjected to immunohistochemical analysis of CYP3A protein. CYP3A5 was the major enzyme of the CYP3A subfamily present at the mRNA level in both normal human lung and lung tumours. CYP3A5 mRNA was detected in normal lung tissue in all eight cases and in tumour tissue in four cases. CYP3A7 mRNA was detected in five cases in normal tissue and in one tumour. Notably, no CYP3A4 mRNA was found in any of the samples. Immunohistochemical staining for CYP3A protein was found in normal lung tissue in each case. Interestingly, all pulmonary carcinomas showed immunostaining for CYP3A, while mRNA for CYP3A enzymes was found in only four cases. In summary, our study indicates a specific expression pattern of the members of the CYP3A subfamily in normal human lung and lung tumours. These findings have potential clinical significance, since it has been recently shown that CYP3A5 catalyzes the activation of the anticancer pro-drugs cyclophosphamide and ifosfamide. Thus, local activation of these agents may take place in pulmonary carcinomas and surrounding normal tissues.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. 0J Biol Chem 264:10388–10395
Beaune P, Kremers P, Letawe-Goujon F, Gielen JE (1985) Monoclonal antibodies against human liver cytochrome P-450. Biochem Pharmacol 34:3547–3552
Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR (1995) Pharmacokinetics, metabolism and clincal effect of ifosfamide in breast cancer patients. Eur J Cancer 31A:69–76
Botsch S, Gautier J-C, Beaune P, Eichelbaum M, Kroemer HK (1993) Identification and characterization of the cytochrome P 450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 43:120–126
Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629–5637
Dechant KL, Brogden RN, Pilkington T, Faulds D (1991) Ifosfamide/mesna: a review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42:428–467
Fritz P, Mueller J, Wegner G, Braun U, Grau A, Tuczek HV, Moessner E, Schenk R (1985) Immunohistochemie: Theoretische Möglichkeiten, praktische Anwendungen. Zlbl Allg Pathol Anat 130:187–193
Fritz P, Behrle E, Beaune P, Eichelbaum M, Kroemer HK (1993) Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P 450 3A and glutathione-S-transferase. Histochemistry 99:443–451
Gillam EMJ, Guo Z, Ueng Y-F, Yamazaki H, Cock I, Reilly PEB, Hooper WD, Guengerich FP (1995) Expression of cytochrome P 450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 317:374–384
Gonzalez FJ, Idle JR (1994) Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet 26:59–70
Gonzalez FJ, Schmid BJ, Umeno M, McBride OW, Hardwick JP, Meyer UA, Gelboin HV, Idle JR (1988) Human P 450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P 450PCN1 is nifedipine oxidase. DNA 7:79–86
Guengerich FP (1993) Bioactivation and detoxication of toxic and carcinogenic chemicals. Drug Metab Dispos 21:1–6
Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genomic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051–5060
Hsu SM, Raine L, Fanger H (1981) The use of anti-avidin antibody and avidin-biotin-complex in immunoperoxidase techniques. Am J Clin Pathol 75:816–821
Hultman T, Stahl S, Homes E, Uhlen M (1989) Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid supports. Nucleic Acids Res 17:4937–4946
Kivistö KT, Fritz P, Linder A, Friedel G, Beaune P, Kroemer HK (1995a) Immunohistochemical localization of cytochrome P 4503A in human pulmonary carcinomas and normal bronchial tissue. Histochemistry 103:25–29
Kivistö KT, Linder A, Friedel G, Beaune P, Belloc C, Kroemer HK, Fritz P (1995b) Immunohistochemical localization of cytochrome P 4502E1 in human pulmonary carcinoma and normal bronchial tissue. Virchows Arch 426:243–247
Kolars JC, LowD KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247–259
Komori M, Nishio K, Ohi H, Kitada M, Kamataki T (1989) Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450. J Biochem (Tokyo) 105:161–163
Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144–160
Massaad L, de Waziers I, Ribrag V, Janot F, Beaune PH, Morizet J, Gouyette A, Chabot GG (1992) Comparison of mouse and human colon tumours with regard to phase I and phase II drug-metabolizing enzyme systems. Cancer Res 52:6567–6575
McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, Eggleston JC, Boyd MR, Hines RN (1990) Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 82:1333–1339
Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, Shimada T (1993) Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos 21:1048–1056
Moore MJ (1991) Clinical pharmacokinetics of cyclophosphamide. Clin Phamacokinet 20:194–208
Murray GI, Barnes TS, Sewell HF, Ewen SWB, Melvin WT, Burke MD (1988) The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol 25:465–475
Murray GI, Weaver RJ, Paterson PJ, Ewen SWB, Melvin WT, Burke MD (1993) Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol 169:347–353
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423
Walker D, Ranu HK, Pearson ADJ, Idle JR (1995) Cytochrome P 450 3A5 (CYP3A5) makes a significant contribution to the metabolism in vitro of cyclophosphamide and ifosfamide. Proc Am Assoc Cancer Res 36:2224
Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson ADJ, Idle JR (1995) Cyclophosphamide metabolism in children. Cancer Res 55:803–809
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kivistö, K.T., Griese, EU., Fritz, P. et al. Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn-Schmiedeberg's Arch Pharmacol 353, 207–212 (1996). https://doi.org/10.1007/BF00168759
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168759